Long-term outcome of juvenile idiopathic arthritis following a placebo-controlled trial: sustained benefits of early sulfasalazine treatment.
| Title: | Long-term outcome of juvenile idiopathic arthritis following a placebo-controlled trial: sustained benefits of early sulfasalazine treatment. |
|---|---|
| Authors: | van Rossum MA; Emma Children's Hospital AMC, Paediatric Rheumatology, G8-205, PO Box 22660, 1100 DD Amsterdam, The Netherlands. m.a.vanrossum@amc.uva.nl; van Soesbergen RM; Boers M; Zwinderman AH; Fiselier TJ; Franssen MJ; ten Cate R; van Suijlekom-Smit LW; Wulffraat NM; van Luijk WH; Oostveen JC; Kuis W; Dijkmans BA |
| Corporate Authors: | Dutch Juvenile Idiopathic Arthritis Study group |
| Source: | Annals of the rheumatic diseases [Ann Rheum Dis] 2007 Nov; Vol. 66 (11), pp. 1518-24. Date of Electronic Publication: 2007 May 09. |
| Publication Type: | Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| Language: | English |
| Journal Info: | Publisher: Elsevier Country of Publication: United States NLM ID: 0372355 Publication Model: Print-Electronic Cited Medium: Print ISSN: 0003-4967 (Print) Linking ISSN: 00034967 NLM ISO Abbreviation: Ann Rheum Dis Subsets: MEDLINE |
| Imprint Name(s): | Publication: 2025- : [New York] : Elsevier; Original Publication: London : H.K. Lewis |
| MeSH Terms: | Antirheumatic Agents/*therapeutic use ; Arthritis, Juvenile/*drug therapy ; Sulfasalazine/*therapeutic use; Antirheumatic Agents/administration & dosage ; Methotrexate/therapeutic use ; Sulfasalazine/administration & dosage ; Adolescent ; Child ; Child, Preschool ; Drug Administration Schedule ; Drug Therapy, Combination ; Epidemiologic Methods ; Female ; Humans ; Male ; Patient Compliance ; Severity of Illness Index ; Treatment Outcome |
| Abstract: | Objectives: A previous 24-week randomised trial demonstrated that sulfasalazine (SSZ) treatment was superior to placebo (PLAC) in suppressing disease activity in patients with oligo- and polyarticular onset juvenile idiopathic arthritis (JIA). The current study determines the long-term outcome of the trial participants and evaluates whether the benefits of SSZ allocation are sustained over time.; Methods: Between 2001 and 2003, 32 SSZ and 29 PLAC patients (90% of all patients) were prospectively examined clinically and by chart review, median 9 years (range 7 to 10) after trial inclusion. In the follow-up assessment, variables of the American College of Rheumatology Pediatric 30 (ACR Pedi 30) criteria were collected. The assessor was blinded to trial treatment allocation.; Results: After the trial, patients had been routinely followed in rheumatology referral centres, and treated at the discretion of the attending physician. Almost all patients continued or started disease-modifying antirheumatic drugs (DMARDs) (SSZ 91%, PLAC 93%; SSZ treatment in about 80%). DMARD treatment appeared less intensive in the SSZ group as evidenced by a significantly shorter duration of SSZ use (median 2.5 vs 5.2 years; p = 0.02) and a trend towards less use of methotrexate and other DMARDs. More than one-third of the patients reported long periods of non-compliance with DMARD treatment in both groups. At follow-up, 74% of the patients had active joints, and 30% showed active polyarthritis. Almost all outcome scores were better for SSZ compared with PLAC patients. Differences (often exceeding 50%) were significant for the number of active joints, patients' overall well-being, number of patients with episodes of clinical remission off medication (CROM) and duration of these episodes, patients in CROM and ACR Pedi 30 response at follow-up. Additional exploratory analyses performed to detect potential confounders related to patient characteristics or follow-up treatment showed that DMARD treatment compliance was positively correlated with an ACR Pedi 30 response (odds ratio 3.8, 95% confidence interval (CI) 1.1 to 13.4; p = 0.03). Adjusted for compliance, an SSZ patient was 4.2 times as likely as a PLAC patient to be an ACR Pedi 30 responder at follow-up (95% CI 1.3 to 14.3; p = 0.02).; Conclusions: This follow-up study shows that effective suppression of disease activity by SSZ treatment early in active disease in JIA patients has beneficial effects that persist for many years. Given these results, compliance with DMARD treatment deserves serious attention. |
| Comments: | Comment in: Nat Clin Pract Rheumatol. 2008 Jul;4(7):344-5. doi: 10.1038/ncprheum0819.. (PMID: 18493268) |
| References: | Scand J Rheumatol. 2001;30(1):25-30. (PMID: 11252688); J Rheumatol. 2000 Mar;27(3):623-9. (PMID: 10743799); Clin Exp Rheumatol. 2001 Jul-Aug;19(4 Suppl 23):S111-5. (PMID: 11510312); Arthritis Rheum. 2002 Feb;46(2):283-5. (PMID: 11840429); Arthritis Rheum. 2002 Feb;46(2):347-56. (PMID: 11840436); J Rheumatol. 2002 Sep;29(9):1989-99. (PMID: 12233897); Best Pract Res Clin Rheumatol. 2002 Jul;16(3):361-78. (PMID: 12387805); Rheumatology (Oxford). 2002 Dec;41(12):1428-35. (PMID: 12468825); J Rheumatol. 2003 Feb;30(2):386-93. (PMID: 12563700); J Rheumatol. 2003 Feb;30(2):394-400. (PMID: 12563701); J Rheumatol. 2003 Mar;30(3):579-84. (PMID: 12610820); J Rheumatol. 2003 Mar;30(3):585-93. (PMID: 12610821); Arthritis Rheum. 2003 Jul;48(7):1771-4. (PMID: 12847667); J Rheumatol. 2004 Feb;31(2):390-2. (PMID: 14760812); Clin Exp Rheumatol. 2003 Sep-Oct;21(5 Suppl 31):S89-93. (PMID: 14969057); Ann Rheum Dis. 2004 Oct;63(10):1318-26. (PMID: 15361393); Arch Dis Child. 2004 Oct;89(10):943-9. (PMID: 15383439); J Rheumatol. 1982 Jan-Feb;9(1):109-13. (PMID: 7045358); Clin Rheumatol. 1984 Sep;3(3):305-9. (PMID: 6488708); Rheum Dis Clin North Am. 1991 Nov;17(4):891-905. (PMID: 1767079); Arthritis Rheum. 1994 Dec;37(12):1761-9. (PMID: 7986222); J Rheumatol. 1995 Feb;22(2):295-307. (PMID: 7738954); Ann Rheum Dis. 1996 Jan;55(1):73-5. (PMID: 8572741); J Rheumatol. 1995 Dec;22(12):2208-13. (PMID: 8835550); Ann Rheum Dis. 1997 Mar;56(3):197-200. (PMID: 9135226); J Rheumatol. 1997 May;24(5):945-51. (PMID: 9150087); Arthritis Rheum. 1997 Jul;40(7):1202-9. (PMID: 9214419); Arthritis Rheum. 1998 May;41(5):808-16. (PMID: 9588731); J Rheumatol. 2004 Nov;31(11):2290-4. (PMID: 15517647); Arthritis Rheum. 2005 Feb;52(2):382-5. (PMID: 15692991); N Engl J Med. 2005 Apr 21;352(16):1655-66. (PMID: 15843668); Arthritis Rheum. 2005 Sep;52(9):2865-72. (PMID: 16142707); JAMA. 2005 Oct 5;294(13):1671-84. (PMID: 16204667); Clin Exp Rheumatol. 2001 Jul-Aug;19(4 Suppl 23):S1-9. (PMID: 11510308); Pediatr Res. 2000 Mar;47(3):316-23. (PMID: 10709729); Rheumatology (Oxford). 2000 Feb;39(2):198-204. (PMID: 10725073) |
| Substance Nomenclature: | 0 (Antirheumatic Agents); 3XC8GUZ6CB (Sulfasalazine); YL5FZ2Y5U1 (Methotrexate) |
| Entry Date(s): | Date Created: 20070511 Date Completed: 20071109 Latest Revision: 20250214 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC2111611 |
| DOI: | 10.1136/ard.2006.064717 |
| PMID: | 17491099 |
| Database: | MEDLINE |
Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't